Personalized Peptide Vaccination in Cancer Immunotherapy

Personalized peptide vaccination represents a precision immunotherapy approach in which patient-specific tumour antigens or neoantigens are identified and formulated into short peptides designed to bind individual HLA molecules. Delivered alongside adjuvants, these vaccines prime dendritic cells to present the selected epitopes, inducing robust cytotoxic T lymphocyte (CTL) responses targeted against malignant cells. Advances in genomics and proteomics have enabled rapid identification of mutation‐derived neoantigens, facilitating bespoke vaccine design. Nanoparticle carriers, long-peptide constructs and novel adjuvants augment antigen presentation and T-cell activation, while combination with checkpoint inhibitors can overcome tumour-induced immunosuppression. Clinical studies across melanoma, prostate, oesophageal and lung cancers demonstrate proof of concept, with immune correlates such as CTL frequency, cytokine profiles and tumour infiltrating lymphocytes serving as markers of efficacy. Challenges remain in optimising peptide selection, delivery platforms and biomarkers of response, but the global significance of this modality lies in its capacity to generate highly specific antitumour immunity with favourable safety profiles.

Research from Nature Portfolio

A recent study introduced a multi-epitope long peptide vaccine that incorporates several tumour-associated antigenic sequences into a single construct. In preclinical HLA-A*2402 knock-in models, this vaccine elicited simultaneous CTL responses against multiple epitopes, demonstrating superior magnitude and breadth compared to short-peptide formulations. When combined with PD-1/PD-L1 blockade, the long-peptide vaccine achieved synergistic antitumour activity, amplifying T-cell infiltration and tumour regression. These findings establish a platform for multi-epitope long peptides as a means to overcome antigenic heterogeneity and enhance clinical efficacy of peptide-based immunotherapy.

Personalized Peptide Vaccination in Cancer Immunotherapy publication trend

The graph below shows the total number of articles in personalized peptide vaccination in cancer immunotherapy across all publications each year (not limited to Nature Index journals).

Technical terms

Neoantigen: A peptide derived from tumour-specific somatic mutations not present in normal tissue.

Epitope: The minimal peptide fragment recognised by T-cell receptors in the context of an HLA molecule.

Adjuvant: An immunostimulatory agent co-administered with antigen to enhance immune activation and vaccine efficacy.

HLA restriction: The requirement that a peptide binds a patient’s specific major histocompatibility complex (HLA) allele to be presented to T cells.

Cytotoxic T lymphocyte (CTL): A CD8+ T cell subset capable of directly killing antigen-expressing target cells through perforin- and granzyme-mediated pathways.

References

1. TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice. Scientific Reports (2020).
2. PLGA-PEI nanoparticle covered with poly(I:C) for personalised cancer immunotherapy. Drug Delivery and Translational Research (2024).
3. A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma. Esophagus (2024).
4. Frequencies of an Immunogenic HER-2/neu Epitope of CD8+ T Lymphocytes Predict Favorable Clinical Outcomes in Prostate Cancer. International Journal of Molecular Sciences (2023).